Clinical trial · Interventional
The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery
NCT02052557CI-TRIAL-00049337completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Diverticulitis | — | UNRESOLVED | — |
| Post-operative Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine | Drug | — | UNRESOLVED |
| Bupivacaine liposome suspension | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Bupivacaine
- description
- 30 milliliters (ml) of 0.5% marcaine with epinephrine
- interventionNames
- Drug: Bupivacaine
- type
- ACTIVE_COMPARATOR
- label
- Bupivacaine liposome suspension
- description
- exparel 20ml, diluted with 10ml sterile saline for total of 30ml
- interventionNames
- Drug: Bupivacaine liposome suspension
Primary outcomes (1)
- measure
- PCA (Patient Controlled Analgesia) Usage
- timeFrame
- 48 hours post operatively
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Elective colon resection for both benign and malignant disease * Laparoscopic, robotic and open techniques Exclusion Criteria: * emergent colon cases * cases preformed by surgeons other than Dr. Raman or Dr. Kraemer * pregnant patients * patients currently breast feeding * patients under the age of 18 * other patients unable to give informed consent * bupivacaine use within 96 hours * allergy to amide anesthetics * prisoners * caution will be used in patients with renal or hepatic failure.
References
Publications (1)
- DERIVEDKnudson RA, Dunlavy PW, Franko J, Raman SR, Kraemer SR. Effectiveness of Liposomal Bupivacaine in Colorectal Surgery: A Pragmatic Nonsponsored Prospective Randomized Double Blinded Trial in a Community Hospital. Dis Colon Rectum. 2016 Sep;59(9):862-9. doi: 10.1097/DCR.0000000000000648. PMID 27505115